Gastrointestinal Cancer | Specialty

Treatment Updates Move Neuroendocrine Tumor Paradigm Forward

October 31st 2018

Syma Iqbal, MD, discusses the evolving treatment paradigm of neuroendocrine tumors.

Role of Immunotherapy May Expand in Gastric/GEJ Cancers

October 31st 2018

The second-line treatment of gastric and gastroesophageal junction cancers has shifted considerably in the last few years, due in part to the addition of immunotherapy for select subgroups of patients.

Dr. Cercek on Induction Chemotherapy in Mismatch Repair Deficient Rectal Cancer

October 29th 2018

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses induction chemotherapy in patients with mismatch repair deficient rectal cancer.

Real-World Results Reveal Regorafenib Tolerability in mCRC

October 29th 2018

Juan Manuel O’Connor, MD, discusses the final results of the CORRELATE regorafenib study in patients with metastatic colorectal cancer, emphasizing the importance of real-world data.

Dr. Lenz on the Benefit of Regorafenib in CRC

October 26th 2018

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the benefit of regorafenib (Stivarga) in the treatment of patients with colorectal cancer (CRC).

FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer

October 26th 2018

The FDA has granted a priority review to a supplemental new drug application for TAS-102 for use in previously treated patients with advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.

Dr. Shiller on Molecular Diagnostics in Gastrointestinal Cancers

October 23rd 2018

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses molecular diagnostics in gastrointestinal (GI) cancers.

Sequencing Strategies, Combinations Mark Next Steps in HCC

October 23rd 2018

Josep M. Llovet, MD, PhD, discusses the rapidly evolving treatment landscape for hepatocellular carcinoma and the work that lies ahead.

Dr. Iqbal on Second- and Third-Line Therapies in Gastric Cancer

October 23rd 2018

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses second- and third-line therapies in gastric cancer.

Neoadjuvant Nivolumab Plus Ipilimumab Active in dMMR Early-Stage Colon Cancer

October 23rd 2018

First results from a study of neoadjuvant ipilimumab plus nivolumab in patients with early-stage colon cancer found a major pathologic response achieved in all 7 patients with mismatch repair deficient tumors.

Trifluridine/Tipiracil Extends Survival in Heavily Pretreated Gastric/GEJ Cancer

October 22nd 2018

Trifluridine/tipiracil reduces the risk of death by about one-third compared with placebo in patients with heavily pretreated gastric or gastroesophageal junction cancer.

Atezolizumab Plus Bevacizumab Shows Durable Activity in Advanced HCC

October 22nd 2018

The combination of the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab showed promising and durable antitumor activity in a phase Ib study of patients with advanced hepatocellular carcinoma.

Metastatic CRC: Moving Into the Future

October 22nd 2018

Precision Medicine Further Explored in Metastatic CRC

October 22nd 2018

Immunotherapy in MSS Colorectal Cancer

October 22nd 2018

Immunotherapy Regimens in dMMR/MSI-High Metastatic CRC

October 22nd 2018

Significance of MSI Status and TMB in Metastatic CRC

October 22nd 2018

Triplet Regimens in BRAF-Mutant Metastatic CRC

October 22nd 2018

Targeting BRAF in Metastatic CRC

October 22nd 2018

Tumor Sidedness in CRC: Distinguishing Factors

October 22nd 2018